SCHEMBL64050

SCHEMBL64050

Cc1noc(C)c1S(=O)(=O)NC12CCC(CC1)Cn1c2nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.46
CYP2C9 P11712 1/20 0.42
ALDH1A1 P00352 4/20 0.39
MAPT P10636 1/20 0.39
HSD17B10 Q99714 1/20 0.39
HTT P42858 1/20 0.39
PKM P14618 1/20 0.38
STAT3 P40763 2/20 0.38
KCNE1 P15382 1/20 0.38
CCR1 P32246 1/20 0.38
KCNQ1 P51787 1/20 0.38
TP53 P04637 1/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
NR3C1 P04150 2/20 0.35
PGR P06401 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL62804 0.88 KCNH2 (0.45) KCNH2CYP2C9ALDH1A1HTTSTAT3
SCHEMBL52328 0.86 KCNH2 (0.51) KCNH2CYP2C9ALDH1A1KCNE1CCR1
SCHEMBL53061 0.85 KCNH2 (0.57) KCNH2CYP2C9ALDH1A1KCNE1CCR1
SCHEMBL52509 0.85 KCNH2 (0.49) KCNH2CYP2C9ALDH1A1MAPTKCNE1
SCHEMBL63575 0.85 KCNH2 (0.47) KCNH2CYP2C9KCNE1CCR1KCNQ1
SCHEMBL52505 0.85 KCNH2 (0.42) KCNH2CYP2C9ALDH1A1MAPTHSD17B10
SCHEMBL64598 0.84 KCNH2 (0.46) KCNH2CYP2C9ALDH1A1MAPTKCNE1
SCHEMBL52342 0.83 KCNH2 (0.50) KCNH2CYP2C9MAPTKCNE1CCR1
SCHEMBL64054 0.83 KCNH2 (0.45) KCNH2CYP2C9MAPTSTAT3KCNE1
Hydrochloric Acid SCHEMBL420026 0.82 KCNH2 (0.49) KCNH2CYP2C9MAPTKCNE1CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280981-B1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-04-23 EP disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG KCNH2 3969/4885CYP2C9 602/4885ALDH1A1 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.